GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Julian S. Gangolli sold 671,928 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $14.84, for a total transaction of $9,971,411.52. Following the sale, the insider now owns 510,352 shares of the company’s stock, valued at approximately $7,573,623.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of GWPH stock opened at $178.98 on Thursday. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00. The firm has a market capitalization of $5.22 billion, a PE ratio of -16.95 and a beta of 2.75. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.81 and a quick ratio of 7.19.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The company had revenue of $39.20 million during the quarter, compared to analyst estimates of $12.32 million. During the same quarter in the previous year, the business earned ($3.12) EPS. The firm’s revenue was up 1189.5% on a year-over-year basis. Equities analysts expect that GW Pharmaceuticals PLC- will post -4.55 EPS for the current fiscal year.

Several brokerages have commented on GWPH. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $198.00 target price for the company in a research report on Saturday, March 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $229.00 target price (up previously from $196.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 7th. Oppenheimer cut shares of GW Pharmaceuticals PLC- from an “outperform” rating to a “market perform” rating and set a $195.00 target price for the company. in a research report on Wednesday, May 8th. Finally, Piper Jaffray Companies upped their target price on shares of GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $205.40.

Hedge funds have recently made changes to their positions in the company. Horan Capital Advisors LLC. acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $25,000. Exane Derivatives acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $28,000. TCG Advisors LP acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $29,000. Institutional & Family Asset Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $31,000. Finally, Paragon Capital Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $34,000. 79.60% of the stock is owned by institutional investors.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2019/05/16/gw-pharmaceuticals-plc-gwph-insider-sells-9971411-52-in-stock.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: Understanding Analyst Recommendations

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.